10x Genomics Expands Autoimmune Biomarker Research With Two New Collaborations

By Public Technologies
  • 10x Genomics announced two research collaborations to identify blood-based biomarkers for autoimmune disease activity and treatment response, expanding research into Europe and Asia.
  • Both collaborations plan to use Flex Apex to analyze blood samples over time at single-cell resolution, linking immune profiles with clinical outcomes.
  • Charité and DRFZ plan a multiyear study involving 750 patients with rheumatoid arthritis, lupus or psoriatic arthritis to identify disease-activity and treatment-response biomarkers.
  • Seoul National University researchers will study moderate-to-severe alopecia areata, seeking biomarkers that predict response to JAK inhibitor therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611161605PR_NEWS_USPR_____LA98803) on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.